Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
Compugen (CGEN) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before U.S. markets open. The clinical-stage cancer immunotherapy company will host a conference call and webcast at 8:30 am ET, where management will review financial results and provide a corporate update.
Investors can access the conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A live webcast will be available through Compugen's website, with a replay accessible afterward.
Compugen (CGEN) ha annunciato che rilascerà i propri risultati finanziari per il quarto trimestre e l'intero anno 2024 martedì 4 marzo 2025, prima dell'apertura dei mercati statunitensi. L'azienda, attiva nello sviluppo di terapie immunologiche contro il cancro, ospiterà una conferenza telefonica e una diretta web alle 8:30 ET, durante la quale la direzione esaminerà i risultati finanziari e fornirà aggiornamenti aziendali.
Gli investitori possono accedere alla conferenza telefonica componendo il numero 1-866-744-5399 dagli Stati Uniti o il +972-3-918-0644 a livello internazionale. Una diretta web sarà disponibile sul sito di Compugen, con una registrazione accessibile successivamente.
Compugen (CGEN) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el martes 4 de marzo de 2025, antes de la apertura de los mercados en EE. UU. La empresa de inmunoterapia contra el cáncer en etapa clínica llevará a cabo una llamada de conferencia y una transmisión web a las 8:30 am ET, donde la dirección revisará los resultados financieros y proporcionará una actualización corporativa.
Los inversores pueden acceder a la llamada de conferencia marcando el 1-866-744-5399 desde EE. UU. o el +972-3-918-0644 internacionalmente. Una transmisión en vivo estará disponible a través del sitio web de Compugen, con una repetición accesible posteriormente.
Compugen (CGEN)은 2024년 4분기 및 연간 재무 결과를 2025년 3월 4일 화요일, 미국 시장 개장 전에 발표할 것이라고 발표했습니다. 임상 단계의 암 면역 치료 회사는 동부 표준시 오전 8시 30분에 경영진이 재무 결과를 검토하고 기업 업데이트를 제공하는 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다.
투자자들은 미국에서 1-866-744-5399로 전화하거나 국제적으로 +972-3-918-0644로 다이얼하여 컨퍼런스 콜에 접속할 수 있습니다. Compugen의 웹사이트를 통해 생중계가 제공되며, 이후 재생도 가능합니다.
Compugen (CGEN) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le mardi 4 mars 2025, avant l'ouverture des marchés américains. La société de thérapie immunologique contre le cancer en phase clinique organisera une conférence téléphonique et un webinaire à 8h30 ET, où la direction passera en revue les résultats financiers et fournira une mise à jour de l'entreprise.
Les investisseurs peuvent accéder à la conférence téléphonique en composant le 1-866-744-5399 depuis les États-Unis ou le +972-3-918-0644 à l'international. Un webinaire en direct sera disponible sur le site de Compugen, avec un replay accessible par la suite.
Compugen (CGEN) hat angekündigt, dass es am Dienstag, den 4. März 2025, vor der Eröffnung der US-Märkte seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlichen wird. Das Unternehmen für Krebsimmuntherapie in der klinischen Phase wird um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, in dem das Management die Finanzergebnisse überprüfen und ein Unternehmensupdate geben wird.
Investoren können an der Telefonkonferenz teilnehmen, indem sie in den USA 1-866-744-5399 oder international +972-3-918-0644 wählen. Ein Live-Webcast wird über die Website von Compugen verfügbar sein, und eine Wiederholung wird anschließend zugänglich sein.
- None.
- None.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-march-4-2025-302378746.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release its Q4 and full year 2024 earnings?
What time is Compugen's (CGEN) Q4 2024 earnings call?
How can investors access Compugen's (CGEN) Q4 2024 earnings call?
Will there be a replay available for Compugen's (CGEN) Q4 2024 earnings call?
